PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Consensus rating: Six analysts give PepGen a "Moderate Buy" (five buys, one sell) with an average 12‑month price target of $11.80, though individual targets vary widely from $5 (Wedbush) to $15 (Oppenheimer).
• Shares opened at $1.64 with a market cap of about $113M and a 52‑week range of $1.01–$7.80, leaving the stock trading far below the analysts' average target.
• PepGen reported Q EPS of ($0.27), beating estimates, but sell‑side forecasts still project about ($2.73) EPS for the fiscal year, and institutional investors hold roughly 58% of the stock with several funds adding new positions.

Shares of PepGen, Inc. (NASDAQ:PEPG - Get Free Report) have received an average recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.80.

Several equities research analysts have commented on PEPG shares. Wedbush decreased their target price on shares of PepGen from $9.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings restated a "sell (d-)" rating on shares of PepGen in a research report on Thursday, January 22nd. Oppenheimer started coverage on PepGen in a research note on Wednesday, February 25th. They set an "outperform" rating and a $15.00 price target for the company. Finally, Guggenheim lifted their price target on PepGen from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th.

PepGen Stock Performance

Shares of NASDAQ PEPG opened at $1.64 on Monday. The firm has a market capitalization of $113.35 million, a P/E ratio of -0.68 and a beta of 2.34. PepGen has a one year low of $1.01 and a one year high of $7.80. The company's fifty day moving average is $4.93 and its two-hundred day moving average is $5.20.

PepGen (NASDAQ:PEPG - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.13. On average, sell-side analysts forecast that PepGen will post -2.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Monashee Investment Management LLC acquired a new position in shares of PepGen during the 3rd quarter worth $1,386,000. Boxer Capital Management LLC acquired a new position in shares of PepGen during the 3rd quarter worth $1,155,000. Commodore Capital LP acquired a new position in shares of PepGen during the 3rd quarter worth $10,891,000. Fifth Lane Capital LP acquired a new position in shares of PepGen during the 3rd quarter worth $323,000. Finally, Squarepoint Ops LLC acquired a new position in shares of PepGen during the 4th quarter worth $203,000. Institutional investors and hedge funds own 58.01% of the company's stock.

About PepGen

PepGen, Inc NASDAQ: PEPG is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.